Monday, February 8, 2016 5:44:00 AM PDT | VentureDeal
South San Francisco, California -- Biotechnology company EpiBiome has secured $6 million in its first round of institutional venture capital funding.
EpiBiome is developing "effective and sustainable FDA-approved therapies to combat infectious diseases in humans and in agriculture without the use of antibiotics." Investors in the round included Matrix Capital Management, Alexandria Venture Investments, SV Tech Ventures, ChinaRock Capital Management and Illumina Accelerator Program The company said it would use the funding to continue developing alternatives to small-molecule antibiotics. EpiBiome CEO Nick Conley has been with the firm since August 2013.
Email Page | Print Page
Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?
Start your Free 14 Day Trial now – no obligation or credit card required.
